Ключевые слова:
HPV, HPV16, PZR, sitologiya, Pap-test, vaginal mikroflora, mikrobiologik tekshiruv, reproduktiv yoshdagi ayollar.Библиографические ссылки
1. World Health Organization. Cervical cancer. Geneva: WHO; 2025.
2. World Health Organization. WHO guideline for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention: use of dual-stain cytology to triage women after a positive test for human papillomavirus (HPV). Geneva: WHO; 2024.
3. World Health Organization. Self-care interventions for health and well-being: HPV self-sampling as part of cervical cancer screening. Geneva: WHO; 2023.
4. Wei F, Georges D, Man I, Baussano I, Clifford GM, et al. Causal attribution of human papillomavirus genotypes to invasive cervical cancer worldwide: a systematic analysis of the global literature. Lancet. 2024.
5. International Agency for Research on Cancer. Global attribution of HPV genotypes to invasive cervical cancer: a systematic analysis. Lyon: IARC; 2024.
6. National Cancer Institute. HPV and Cancer. Bethesda: NCI; 2025.
7. Ouh YT, Min KJ, Choi CH, Lee JW, Kim BG, et al. Enhancing cervical cancer screening: review of p16/Ki-67 dual staining as a promising triage strategy. Cancers (Basel). 2024;16(2).
8. Clarke MA, Cheung LC, Castle PE, et al. Recommendations for use of p16/Ki67 dual stain for management of individuals testing positive for human papillomavirus. J Low Genit Tract Dis. 2024.
9. Harper DM, et al. p16/Ki-67 dual stain triage of individuals positive for HPV to detect cervical precancer: review and clinical perspective. Ther Adv Vaccines Immunother. 2025.
10. Schreiberhuber L, Barrett JE, Wang J, et al. Cervical cancer screening using DNA methylation triage in a real-world population. Nat Med. 2024;30 (8):2251-2257.
11. Burdier FR, Nieves L, Rojas M, et al. DNA methylation as a triage tool for cervical cancer screening: a systematic review. Int J Mol Sci. 2024.
12. Xia W, Li Y, Zhang H, et al. DNA methylation triage of human papillomavirus-positive ASC-US women in cervical cancer screening. Cancer Cytopathol. 2026.
13. Thrall MJ, et al. Triage options for positive high-risk HPV results from HPV-based cervical cancer screening: a review of potential alternatives to Papanicolaou test cytology. J Am Soc Cytopathol. 2025.
14. Goldstein A, et al. The future of cervical cancer screening. Int J Womens Health. 2024.
15. Martins TR, et al. Molecular screening for cervical cancer. Genes (Basel). 2025;16(9):1041.
16. Bhatla N, Aoki D, Sharma DN, Sankaranarayanan R. Cancer of the cervix uteri: 2025 update. Int J Gynaecol Obstet. 2025;171 Suppl 1:87-108.
17. Colonetti T, et al. Self-sampling for HPV testing in cervical cancer screening: a systematic review. Healthcare (Basel). 2024.
18. Fullerton MM, et al. HPV self-sampling implementation strategies to engage under-screened women: a scoping review. 2024.
19. Aimagambetova G, et al. Comparison of diagnostic accuracy and acceptability of self-sampling devices for HPV testing in cervical cancer screening. 2024.
20. Otieno JA, et al. Human papillomavirus self-sampling versus provider-collected sampling for cervical cancer screening: acceptability, accuracy and cost-effectiveness. 2024.
21. Cora-Cruz MS, et al. Evaluating human papillomavirus self-sampling among Latinas in the United States: a systematic review. 2024.
22. Oommen AM, et al. Strategies and implementation outcomes of HPV-based cervical screening studies to prevent cervical cancer in India: a systematic review. J Cancer Policy. 2024;42:100513.
23. Goulart RA, et al. Extended HPV genotyping and dual stain for the triage of HPV-positive screening tests: practical considerations for laboratory implementation. 2025.
24. Ntamushigo JC, et al. Review of triage strategies for atypical squamous cells in HPV-based cervical screening. 2025.
25. de Sanjosé S, et al. Design of the HPV-Automated Visual Evaluation (PAVE) study: integrated modern approaches to HPV-based cervical screening. 2023.
